SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...
Bayer SE secures rights to in €310m deal
Under the licence deal, BridgeBio Pharma, Inc. will pass the commercialisation rights for the transthyretin stabiliser acoramidis in Europe where...
Gut bacteria seed autoimmunity-inducers
A unique mechanism, reported by an Irish-French research team underscores an emerging theme in microbiome research: that disruptions to gut bacteria...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....
Swiss vaccine developer Limma Tech get CARB-X grant
LimmaTech said, it will use the grant to advance preclinical development of its hexavalent vaccine candidate targeting Neisseria gonorrheae. Using...
Electrochaea sells biomethane reactor to Again A/S
Like German bio-CH4 producer Electrochea GmbH, Danish Again A/S is using CO2-fxing archaea, but to manufacture carbon-negative chemicals such...